Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Allogene Therapeutics Inc (NQ: ALLO ) 2.720 +0.170 (+6.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,534,770 Open 2.570 Bid (Size) 2.720 (30) Ask (Size) 2.840 (1) Prev. Close 2.550 Today's Range 2.570 - 2.830 52wk Range 2.010 - 5.775 Shares Outstanding 142,183,418 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update October 30, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) October 29, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Performance YTD -24.86% -24.86% 1 Month +4.21% +4.21% 3 Month +9.24% +9.24% 6 Month -9.63% -9.63% 1 Year -22.29% -22.29% More News Read More Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors October 22, 2024 From Artiva Biotherapeutics, Inc. Via GlobeNewswire A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics August 08, 2024 Via Benzinga Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference September 30, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence September 26, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Announces Participation in Upcoming Investor Conferences August 08, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Analyst Ratings For Allogene Therapeutics May 31, 2024 Via Benzinga Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views May 15, 2024 Via Benzinga 7 Biotech Stocks to Buy for Their Game-Changing Potential August 08, 2024 Via InvestorPlace Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update August 07, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update July 31, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges July 19, 2024 Via Benzinga Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL) July 01, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse June 20, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names May 28, 2024 Via InvestorPlace Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit May 23, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 21, 2024 Via Benzinga Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket May 21, 2024 Via Benzinga Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket May 15, 2024 Via Benzinga DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session May 15, 2024 Via Benzinga ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 13, 2024 Via InvestorPlace Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock May 13, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update May 13, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update May 06, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
